Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rui Lyu

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Eclinicalmedicine|January 7, 2026
Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in ChinaTingyu Wang, Yuting Yan, Hui Wang, et al.
Annals of Hematology|February 25, 2025
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphomaYuting Yan, Yanshan Huang, Ying Yu, et al.
Journal of Medicinal Chemistry|November 3, 2025
Design, Syntheses, and Pharmacological Evaluations of Core Ring Expanded Fentanyl Analogues as Potential Counteracting Agents Against Fentanyl Induced Respiratory DepressionAbeje A Silte, Ennian Li, Balaji S Kale, et al.
Annals of Hematology|April 19, 2022
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variantYi Wang, Tingyu Wang, Ying Yu, et al.
Frontiers in Immunology|May 26, 2023
Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemiaWenjie Xiong, Zanzan Wang, Tingyu Wang, et al.
British Journal of Haematology|October 17, 2024
γδ and αβ T-cell large granular lymphocytic leukaemia have similar characteristics and outcomesRui Cui, Ying Yu, Yuxi Li, et al.
The Oncologist|March 10, 2025
Classification of NK-large granular lymphocytic leukemia by CD56 expressionYuxi Li, Rui Cui, Ying Yu, et al.
Nature Communications|May 25, 2026
GPSM1 restricts CD73<sup>+</sup>CD103<sup>+</sup> T<sub>reg</sub> cells in adipose tissue, critical for promoting obesity-related metabolic deteriorationXiao-Rui Lyu, Rui-Bing Qi, Yan-Li Hua, et al.
Blood Advances|May 10, 2022
Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WMJun Wang, Yuting Yan, Wenjie Xiong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2024
Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström MacroglobulinemiaYuting Yan, Ying Yu, Wenjie Xiong, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Eclinicalmedicine|January 7, 2026
Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in ChinaTingyu Wang, Yuting Yan, Hui Wang, et al.
Annals of Hematology|February 25, 2025
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphomaYuting Yan, Yanshan Huang, Ying Yu, et al.
Journal of Medicinal Chemistry|November 3, 2025
Design, Syntheses, and Pharmacological Evaluations of Core Ring Expanded Fentanyl Analogues as Potential Counteracting Agents Against Fentanyl Induced Respiratory DepressionAbeje A Silte, Ennian Li, Balaji S Kale, et al.
Annals of Hematology|April 19, 2022
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variantYi Wang, Tingyu Wang, Ying Yu, et al.
Frontiers in Immunology|May 26, 2023
Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemiaWenjie Xiong, Zanzan Wang, Tingyu Wang, et al.
British Journal of Haematology|October 17, 2024
γδ and αβ T-cell large granular lymphocytic leukaemia have similar characteristics and outcomesRui Cui, Ying Yu, Yuxi Li, et al.
The Oncologist|March 10, 2025
Classification of NK-large granular lymphocytic leukemia by CD56 expressionYuxi Li, Rui Cui, Ying Yu, et al.
Nature Communications|May 25, 2026
GPSM1 restricts CD73<sup>+</sup>CD103<sup>+</sup> T<sub>reg</sub> cells in adipose tissue, critical for promoting obesity-related metabolic deteriorationXiao-Rui Lyu, Rui-Bing Qi, Yan-Li Hua, et al.
Blood Advances|May 10, 2022
Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WMJun Wang, Yuting Yan, Wenjie Xiong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2024
Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström MacroglobulinemiaYuting Yan, Ying Yu, Wenjie Xiong, et al.
Pageof 7